Glenmark Pharmaceuticals' Q1 FY 2026-27 Quarterly Results

Result Summary

• Glenmark Pharmaceuticals Ltd reported a 3.1% quarter-on-quarter (QoQ) increase in its consolidated revenues for the quarter-ended Jun (Q1 FY 2026-27). On a year-on-year (YoY) basis, it witnessed a growth of 24.1%.
• Its expenses for the quarter were up by 7.6% QoQ and 19.8% YoY.
• The net profit increased 60.2% QoQ and increased 927.9% YoY.
• The earnings per share (EPS) of Glenmark Pharmaceuticals Ltd stood at 17.11 during Q1 FY 2026-27.

Financial Statments for Q1 FY 2026-27

Data Source: BSE, Company announcements The securities quoted are exemplary and are not recommendatory. Past performance is not indicative of future results

Company Overview

Glenmark Pharmaceuticals Ltd is a prominent player in the pharmaceutical industry, focusing on the development, manufacture, and marketing of pharmaceutical products. The company's portfolio includes a range of formulations, active pharmaceutical ingredients (APIs), and biopharmaceuticals. Glenmark is known for its innovative approach in developing new molecules and leveraging its research and development capabilities. The company operates globally, with a strong presence in emerging markets. It is renowned for its strategic focus on niche therapeutic areas such as dermatology, respiratory, and oncology. As of the latest updates, there are no specific major developments or events available that could impact the company's current operational strategies.

Revenue

During the first quarter of the fiscal year 2027 (Q1FY27), Glenmark Pharmaceuticals reported a total income of ₹4084.25 crores. This reflects a quarter-over-quarter (QoQ) increase of 3.1% compared to the ₹3959.67 crores reported in the fourth quarter of fiscal year 2026 (Q4FY26). On a year-over-year (YoY) basis, the total income increased by 24.1% from ₹3290.88 crores in the first quarter of fiscal year 2026 (Q1FY26). Such growth in revenue indicates a robust period for Glenmark, showing an expansion in its market reach or product uptake. The consistent increase in total income over the periods reflects a positive trajectory in the company's revenue-generating capabilities.

Profitability

Glenmark's profitability metrics for Q1FY27 show significant improvement over both the previous quarter and the same quarter last year. The company achieved a profit before tax (PBT) of ₹643.39 crores, marking a 65.9% increase QoQ compared to ₹387.77 crores in Q4FY26, and a remarkable 573.1% increase YoY from ₹95.58 crores in Q1FY26. The tax expense for Q1FY27 was ₹160.56 crores, showing an 85.7% QoQ increase and a 230.4% YoY increase. Consequently, the profit after tax (PAT) for Q1FY27 stood at ₹482.82 crores, up by 60.2% QoQ and 927.9% YoY from ₹46.97 crores in Q1FY26. Earnings per share (EPS) followed a similar trend, increasing to ₹17.11 in Q1FY27 from ₹10.68 in Q4FY26 and ₹1.66 in Q1FY26, reflecting a 930.7% YoY increase. These figures portray a substantial improvement in the company's profitability during this period.

Operating Metrics

The total expenses for Glenmark in Q1FY27 were ₹3440.86 crores, which represents a 7.6% increase QoQ from ₹3198.50 crores in Q4FY26, and a 19.8% increase YoY from ₹2872.08 crores in Q1FY26. This indicates a rise in operating costs alongside the increase in total income. The proportionate increase in expenses relative to income suggests a scaling up of operations. Despite this, Glenmark has managed to maintain a healthy profit margin, as evidenced by the substantial growth in profits. The company's operating metrics highlight its ability to manage cost escalations while maintaining revenue growth, which is critical for sustaining long-term profitability.